A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease
- 15 October 2011
- journal article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 12 (17), 2613-2626
- https://doi.org/10.1517/14656566.2011.628935
Abstract
(2011). A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy: Vol. 12, No. 17, pp. 2613-2626. doi: 10.1517/14656566.2011.628935This publication has 36 references indexed in Scilit:
- Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activitiesThorax, 2009
- In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisineBioorganic & Medicinal Chemistry Letters, 2005
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Smoking and Lung Function of Lung Health Study Participants after 11 YearsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The Impact of Aging and Smoking on the Future Burden of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónicaArchivos de Bronconeumología, 2001
- Geographic Variations in Prevalence and Underdiagnosis of COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- The Prevalence of COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1JAMA, 1994